Associated products


Our Abpromise guarantee covers the use of ab177141 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Applications

    Blocking - Blocking peptide for Anti-RUNX1 / AML1 + RUNX3 + RUNX2 antibody [EPR3099] (ab92336)

  • Form

  • Additional notes

    - First try to dissolve a small amount of peptide in either water or buffer. The more charged residues on a peptide, the more soluble it is in aqueous solutions.
    - If the peptide doesn’t dissolve try an organic solvent e.g. DMSO, then dilute using water or buffer.
    - Consider that any solvent used must be compatible with your assay. If a peptide does not dissolve and you need to recover it, lyophilise to remove the solvent.
    - Gentle warming and sonication can effectively aid peptide solubilisation. If the solution is cloudy or has gelled the peptide may be in suspension rather than solubilised.
    - Peptides containing cysteine are easily oxidised, so should be prepared in solution just prior to use.

  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped at 4°C. Store at -20°C.

General Info

  • Alternative names

    • Acute myeloid leukemia 1
    • Acute myeloid leukemia 1 protein
    • alpha subunit core binding factor
    • AML 1
    • AML1
    • AML1 EVI 1
    • AML1 EVI 1 fusion protein
    • Aml1 oncogene
    • AMLCR 1
    • AMLCR1
    • CBF alpha 2
    • CBF-alpha-2
    • CBFA 2
    • CBFA2
    • Core binding factor alpha 2 subunit
    • Core binding factor runt domain alpha subunit 2
    • Core-binding factor subunit alpha-2
    • EVI 1
    • EVI1
    • HGNC
    • Oncogene AML 1
    • Oncogene AML-1
    • OTTHUMP00000108696
    • OTTHUMP00000108697
    • OTTHUMP00000108699
    • OTTHUMP00000108700
    • OTTHUMP00000108702
    • PEA2 alpha B
    • PEA2-alpha B
    • PEBP2 alpha B
    • PEBP2-alpha B
    • PEBP2A2
    • PEBP2aB
    • Polyomavirus enhancer binding protein 2 alpha B subunit
    • Polyomavirus enhancer-binding protein 2 alpha B subunit
    • Run1
    • Runt related transcription factor 1
    • Runt-related transcription factor 1
    • RUNX 1
    • Runx1
    • SL3 3 enhancer factor 1 alpha B subunit
    • SL3-3 enhancer factor 1 alpha B subunit
    • SL3/AKV core binding factor alpha B subunit
    • SL3/AKV core-binding factor alpha B subunit
    see all
  • Function

    CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL-3 and GM-CSF promoters. The alpha subunit binds DNA and appears to have a role in the development of normal hematopoiesis. Isoform AML-1L interferes with the transactivation activity of RUNX1. Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the mouse BLK promoter. Inhibits MYST4-dependent transcriptional activation.
  • Tissue specificity

    Expressed in all tissues examined except brain and heart. Highest levels in thymus, bone marrow and peripheral blood.
  • Involvement in disease

    Note=A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1.
    Note=A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP or MECOM.
    Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP or MECOM.
    Note=A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.
    Note=A chromosomal aberration involving RUNX1 is found in acute leukemia. Translocation t(11,21)(q13;q22) that forms a MACROD1-RUNX1 fusion protein.
    Defects in RUNX1 are the cause of familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]. FPDMM is an autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia.
    Note=A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.
    Note=A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.
  • Sequence similarities

    Contains 1 Runt domain.
  • Domain

    A proline/serine/threonine rich region at the C-terminus is necessary for transcriptional activation of target genes.
  • Post-translational

    Phosphorylated in its C-terminus upon IL-6 treatment. Phosphorylation enhances interaction with MYST3.
  • Cellular localization

  • Information by UniProt


ab177141 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab177141.
Please use the links above to contact us or submit feedback about this product.

For licensing inquiries, please contact

Sign up